Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eicosapentaenoic acid - SLA Pharma

Next Previous
Drug Profile

Eicosapentaenoic acid - SLA Pharma

Alternative Names: ALFA; EPA-FFA - SLA Pharma; EPA-FFA gastro-resistant capsules - SLA Pharma; EPAspire™

Latest Information Update: 02 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KD Pharma; SLA Pharma
  • Developer KD Pharma; SLA Pharma; University of Bologna
  • Class Antihyperlipidaemics; Eicosanoids; Omega 3 fatty acids; Small molecules
  • Mechanism of Action Arachidonic acid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Familial adenomatous polyposis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Familial adenomatous polyposis
  • Phase I/II Colorectal cancer; Ulcerative colitis
  • No development reported Crohn's disease; Intestinal polyps
  • Discontinued COVID 2019 infections

Most Recent Events

  • 02 Feb 2026 Discontinued - Phase-III for COVID-2019 infections (In the elderly, In adults) in Spain (PO)
  • 02 Feb 2026 Discontinued - Phase-III for COVID-2019 infections (In the elderly, In adults) in United Kingdom (PO)
  • 08 Jan 2021 Phase-III clinical trials in COVID-2019 infections (In adults, In the elderly) in Spain (PO) (NCT04335032) (EudraCT2020-001396-33)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top